Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, fondaparinux sodium (Arixtra®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with acute symptomatic spontaneous superficial vein thrombosis of the lower limbs without concomitant deep-vein thrombosis. |
||
|
||
Medicine details |
||
| Medicine name | fondaparinux sodium (Arixtra®) | |
| Formulation | Solution for injection | |
| Reference number | 1339 | |
| Indication | Treatment of adult patients with acute symptomatic spontaneous superficial vein thrombosis of the lower limbs without concomitant deep-vein thrombosis |
|
| Company | GlaxoSmithKline | |
| BNF chapter | Cardiovascular system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 01/11/2011 | |